• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Radioactive Iodine Treatment for Thyroid Cancer: How Long to Wait to Become Pregnant?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Recommendations for pregnancy timing following radioactive iodine treatment (RAIT) after thyroidectomy for differentiated thyroid carcinoma suggest waiting 6 to 12 months
  • Hye et al. (JAMA Intern Med., 2019) sought to ascertain whether RAIT was associated with an increase in adverse pregnancy outcomes and the appropriate interval to conception

METHODS:

  • Population-based cohort study
  • Setting
    • Health Insurance Review and Assessment database of South Korea
  • Participants
    • Women 20-49 years
    • Underwent thyroidectomy for the treatment of differentiated thyroid carcinoma
  • Cohorts
    • Surgery alone
    • Surgery followed by RAIT
  • Study design and data analysis
    • Pregnancy outcomes data reviewed
    • Multivariate logistic regression models used to control for confounding
  • Primary outcomes
    • Rates of abortion (both spontaneous and induced, as the database could not distinguish between the two)
    • Preterm delivery
    • Congenital malformation

RESULTS:

  • 111,459 women included
    • Surgery alone: 53.4%
    • Surgery and RAIT: 46.6%
  • Pregnancies: 9.7% | Mean age at conception: 33.3 years
  • No significant differences for the following
    • Abortion | Preterm delivery | Congenital malformation
  • Congenital malformations rates based on interval between RAIT and conception
    • 0 to 5 months: 13.3%
    • 6 to 11 months: 7.9%
    • 12 to 23 months: 8.3%
    • ≥24 months: 9.6%
  • Congenital malformations were more likely in conceptions that occurred 0 to 5 months after RAIT compared with conceptions that occurred 12 to 23 months after RAIT
    • Adjusted odds ratio (OR) 1.74 (95% CI, 1.01 to 2.97; P = 0.04)
  • Congenital malformations noted in the 0 to 5 month post RAIT cohort included
    • 6 CVS | 4 MSK | 3 urinary system | 1 each for CNS, respiratory system, lip and palate, and genital organs
  • Abortion rates based on interval between RAIT and conception
    • 0 to 5 months: 60.6%
    • 6 to 11 months: 30.1%
    • 12 to 23 months: 27.4%
    • ≥24 months: 31.9%

CONCLUSION:

  • This large-scale study demonstrated that RAIT was not associated with malformations and increased miscarriage if conception occurs ≥6 months following treatment

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More »


Learn More – Primary Sources:

Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Is There a Relationship between Magnetic Field Radiation and an Increased Risk of Miscarriage?
The InPreSS data: Are β-Blockers Associated with Increased Risk of Congenital Malformations?
Are Offspring of IVF/ICSI Pregnancies at Higher Risk for Congenital Heart Defects?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site